Recurrent Acute Myeloid Leukemia (DBCOND0111432)

Identifiers

Synonyms

Acute myeloid leukaemia recurrent / Acute, recurrent Myeloid leukaemia / Acute, recurrent Myeloid Leukemia / Acute Myeloid Leukemia Recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03957915	Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia	No drug interventions	treatment	0	recruiting
NCT03825146	The Effects of AMPC in the Treatments of Refractory or Relapsed AML	No drug interventions	treatment	1	unknown_status
NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	Azacitidine	treatment	2	completed
NCT02530034	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	No drug interventions	treatment	1	active_not_recruiting
NCT03661307	Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Decitabine Quizartinib Venetoclax	treatment	1 / 2	recruiting
NCT03816319	TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts	TAK-243	treatment	1	recruiting
NCT04188405	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia	Decitabine Ponatinib Venetoclax	treatment	2	active_not_recruiting
NCT04207190	Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia	Gemtuzumab ozogamicin Talazoparib	treatment	1	completed
NCT04375631	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	Cladribine Cyclophosphamide Cyclosporine Cytarabine Filgrastim Fludarabine Idarubicin Mitoxantrone Mycophenolate mofetil Mycophenolic acid	treatment	1	recruiting
NCT06492707	DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial	No drug interventions	treatment	1	recruiting
NCT04140487	Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm	Azacitidine Gilteritinib Venetoclax	treatment	1 / 2	recruiting
NCT04203316	Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation	Doxazosin Enasidenib Isopropyl alcohol	treatment	2	recruiting
NCT04435691	Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia	Azacitidine Magrolimab Venetoclax	treatment	1 / 2	active_not_recruiting
NCT04493164	CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Ivosidenib	treatment	2	recruiting
NCT05035706	Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors	No drug interventions	treatment	0	recruiting
NCT01892371	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Azacitidine Cytarabine Quizartinib	treatment	1 / 2	completed
NCT02684162	Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant	Guadecitabine	treatment	2	completed
NCT04874194	Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1	Omacetaxine mepesuccinate Venetoclax	treatment	1 / 2	completed
NCT04915612	Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Gemtuzumab ozogamicin	treatment	1	active_not_recruiting
NCT06399640	Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia	Eltanexor Venetoclax	treatment	1	recruiting
NCT06484062	Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes	Cedazuridine Cirtuvivint Decitabine Venetoclax	treatment	1	not_yet_recruiting
NCT03983824	Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia	Benzalkonium Cytarabine Etoposide Mitoxantrone Nedisertib	treatment	1	recruiting
NCT03214562	Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax	treatment	1 / 2	recruiting
NCT05146739	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane	Cytarabine Fludarabine Leucovorin Uproleselan	treatment	1	active_not_recruiting
NCT04746235	Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia	Cedazuridine Decitabine Venetoclax	treatment	2	recruiting
NCT04774393	Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Cedazuridine Decitabine Enasidenib Ivosidenib Venetoclax	treatment	1 / 2	recruiting
NCT04975919	Venetoclax in Combination with Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Cedazuridine Decitabine Venetoclax	treatment	2	active_not_recruiting
NCT05010122	ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cedazuridine Decitabine Gilteritinib Venetoclax	treatment	1 / 2	recruiting
NCT05222984	Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated with Venetoclax	Decitabine Navitoclax Venetoclax	treatment	1	active_not_recruiting
NCT06572631	Multi-antigen Specific CD8+ T Cells with Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from a Matched Donor	Cyclophosphamide Decitabine Fludarabine	treatment	1	not_yet_recruiting
NCT02727803	Personalized NK Cell Therapy in CBT	Activated natural killer cell therapy Aloe vera leaf Ascorbic acid Busulfan CD-16 NK-92 cells Clofarabine Cyclophosphamide Fludarabine Glycerin Mechlorethamine Natural Killer Cell Nicotinamide Rituximab Vitamin A	treatment	2	recruiting
NCT02882321	Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	terminated
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Fludarabine	treatment	1	suspended
NCT04220684	Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML	Cytarabine Fludarabine Natural Killer Cell	treatment	1	recruiting
NCT05799079	Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant	Cedazuridine Decitabine Venetoclax	treatment	2	recruiting
NCT03683433	Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	Azacitidine Doxazosin Enasidenib Isopropyl alcohol	treatment	2	recruiting
NCT03132454	Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	Decitabine Dexamethasone Palbociclib Sorafenib	treatment	1	recruiting
NCT03813147	Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Azacitidine Cytarabine Fludarabine Hydrocortisone Hydrocortisone acetate Methopterin Methotrexate Pevonedistat	treatment	1	completed
NCT02953561	Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Avelumab Azacitidine	treatment	1 / 2	terminated
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT03404193	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	Decitabine Venetoclax	treatment	2	active_not_recruiting
NCT03067571	Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Daratumumab	treatment	2	terminated
NCT03041688	Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia	Decitabine Navtemadlin Venetoclax	treatment	1	active_not_recruiting
NCT03247088	Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant	Busulfan Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Sorafenib Tacrolimus	treatment	1 / 2	active_not_recruiting
NCT06454409	Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Regorafenib Venetoclax	treatment	1	not_yet_recruiting
NCT03745352	Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Pevonedistat	treatment	2	withdrawn
NCT04493099	Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML	Alvocidib Decitabine Venetoclax	treatment	1 / 2	withdrawn
NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Azacitidine Trametinib Venetoclax	treatment	2	completed
NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	Cyclophosphamide Fludarabine Mechlorethamine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT02861417	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT02399917	Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Azacitidine Lirilumab	treatment	2	terminated
NCT03825796	CPX-351 Plus Enasidenib for Relapsed AML	Cytarabine Daunorubicin Doxazosin Enasidenib Isopropyl alcohol	treatment	2	active_not_recruiting
NCT03390296	OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia	Avelumab Azacitidine Gemtuzumab ozogamicin Glasdegib Ivuxolimab Venetoclax	treatment	1 / 2	completed
NCT03881735	Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation	Enasidenib	treatment	2	withdrawn
NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Rimiducid Rivogenlecleucel	treatment	1	withdrawn
NCT03672539	Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Gemtuzumab ozogamicin	treatment	2	recruiting
NCT03772925	Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Belinostat Pevonedistat	treatment	1	active_not_recruiting
NCT03471260	Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies	Azacitidine Ivosidenib Venetoclax	treatment	1 / 2	recruiting
NCT04655391	Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation	Bosutinib Decitabine Doxazosin Enasidenib Gilteritinib Glasdegib Isopropyl alcohol Ivosidenib Venetoclax	treatment	1	withdrawn
NCT04013880	ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Cedazuridine Decitabine Olutasidenib	treatment	1 / 2	withdrawn
NCT06222580	SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation	Gilteritinib Revumenib	treatment	1	recruiting
NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Decitabine Ipilimumab	treatment	1	active_not_recruiting
NCT03009240	Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia	Decitabine Pevonedistat	treatment	1	active_not_recruiting
NCT01640301	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Aldesleukin Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT02392572	ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome	Dordaviprone	treatment	1 / 2	recruiting
NCT03969446	Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Decitabine Pembrolizumab Venetoclax	treatment	1	recruiting
NCT02509546	8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	8-Chloroadenosine Adenosine	treatment	1 / 2	completed
NCT03289910	Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Carboplatin Topotecan Veliparib	treatment	2	active_not_recruiting
NCT03600155	Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT03752138	TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia	Decitabine TK216	treatment	1	withdrawn
NCT04146038	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Azacitidine Decitabine Salsalate Venetoclax	treatment	2	completed
NCT02649764	Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cytarabine Fludarabine Prexasertib	treatment	1	completed
NCT05263284	8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia	8-Chloroadenosine Adenosine Venetoclax	treatment	1	recruiting
NCT04250051	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Filgrastim Fludarabine Ivosidenib	treatment	1	recruiting
NCT03953898	Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	Olaparib	treatment	2	active_not_recruiting
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	Aloe vera leaf Ascorbic acid Busulfan Cyclophosphamide Cyclosporine Fludarabine Glycerin Methopterin Methotrexate Nicotinamide Tacrolimus Vitamin A	treatment	2	withdrawn
NCT03634228	Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia	Cytarabine Venetoclax	treatment	1 / 2	terminated
NCT03629171	Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia	Cytarabine Daunorubicin Venetoclax	treatment	2	recruiting
NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	Ipilimumab Nivolumab	treatment	1	completed
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	Cyclophosphamide Fludarabine Methopterin Methotrexate Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT05627232	Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Daunorubicin Palbociclib Tazemetostat	treatment	1	recruiting
NCT03874052	Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Ruxolitinib Venetoclax	treatment	1	suspended
NCT05396859	Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	Cedazuridine Decitabine Entrectinib	treatment	1	recruiting
NCT03735875	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia	Quizartinib Venetoclax	treatment	1 / 2	completed
NCT03557970	JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia	JNJ-40346527	treatment	2	terminated
NCT04956042	Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Cytarabine Fosciclopirox	treatment	1 / 2	terminated
NCT02551718	High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia	No drug interventions	treatment	Not Available	completed
NCT04047641	Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cladribine Cytarabine Idarubicin Quizartinib	treatment	1 / 2	recruiting
NCT03128034	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	suspended
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT01620216	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	Dasatinib Idelalisib Pacritinib Ponatinib Ruxolitinib Sorafenib Sunitinib	treatment	2	terminated
NCT04752163	DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	Azacitidine Coenzyme M Cortisone Cyclophosphamide Cytarabine Dexamethasone Filgrastim Leucovorin Methopterin Methotrexate Methoxamine Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole	treatment	1 / 2	completed
NCT04158739	Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia	Cytarabine Flotetuzumab	treatment	1	active_not_recruiting
NCT04128748	Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Quizartinib	treatment	1 / 2	recruiting
NCT03670966	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	1 / 2	suspended
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT05320380	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	Cytarabine Daunorubicin Ethanol Fludarabine Hydrocortisone Hydrocortisone succinate IMGN632 Methopterin Methotrexate Prednisolone Prednisone Sodium succinate	treatment	1 / 2	withdrawn
NCT03063944	STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy	Decitabine OPB-111077 Venetoclax	treatment	1	completed
NCT02756572	Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms	Cladribine Cyclosporine Cytarabine Filgrastim Fludarabine Mechlorethamine Melphalan Mitoxantrone Mycophenolate mofetil Sirolimus	treatment	2	completed
NCT05456269	A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS	Bisantrene Cedazuridine Cytarabine Decitabine	treatment	1	withdrawn
NCT04196010	Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms	Cladribine Cytarabine Filgrastim Mitoxantrone	treatment	1	terminated
NCT04905810	Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure	Azacitidine Decitabine Venetoclax	treatment	2	recruiting
NCT04526795	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia	Cytarabine Fludarabine Pegcrisantaspase	treatment	1	active_not_recruiting
NCT03701295	Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement	Azacitidine Pinometostat	treatment	1 / 2	completed
NCT02115295	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Cladribine Cytarabine Gilteritinib Idarubicin Midostaurin Venetoclax	treatment	2	recruiting
NCT05441514	Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Cobimetinib Doxazosin Enasidenib Isopropyl alcohol	treatment	1	recruiting
NCT02083250	Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	Aloe vera leaf Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Ascorbic acid Busulfan Clofarabine Fludarabine Glycerin Nicotinamide Vitamin A Vorinostat	treatment	1	completed
NCT02257138	Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia	Decitabine Ruxolitinib	treatment	1 / 2	completed
NCT05735184	A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML	Azacitidine Cytarabine Daunorubicin Venetoclax Ziftomenib	treatment	1	recruiting
NCT06152809	CIML NK Cells With Venetoclax for AML	Aldesleukin Natural Killer Cell Venetoclax	treatment	1	active_not_recruiting
NCT04050280	CLAG-GO for Patients With Persistent, Relapsed or Refractory AML	Cladribine Cytarabine Filgrastim Gemtuzumab ozogamicin	treatment	2	recruiting
NCT05574608	Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia	Natural Killer Cell	treatment	0	recruiting